心力健丸治疗心肺气虚、血瘀水停型慢性心衰的临床观察
发布时间：2018-12-16 16:50
【摘要】：目的:本次临床观察是通过运用心力健丸联合西药治疗心肺气虚、血瘀水停型慢性心力衰竭患者并观察其治疗效果,从理论方面探索和分析作用机制为慢性心力衰竭的治疗提供新的中成药制剂,从而拓宽慢性心力衰竭的治疗方法,便于实际运用。方法:选择武汉市黄陂区中医院心血管科2015年12月-2016年12月中心肺气虚、血瘀水停型慢性心衰住院患者60例,年龄为50-75岁区间内,心功能处于II-III级(NYHA分级)。将60例患者随机分为治疗组30例和对照组30例,治疗组口服心力健丸与西药治疗,对照组按常规西药治疗。心力健丸为我院研发制剂,由本院煎药室制成水丸,服药疗程为3个月,服用方法为每日3次,每次15粒。分别于治疗前后观察中医症状积分、NYHA心功能分级、Lee氏心衰疗效积分、LVEF、NT-pro BNP的水平、血液生化指标。结果:经过3个月的治疗,两组患者都取得了良好的治疗效果,临床症状积分的结果显示治疗后两组患者的中医证侯积分及Lee氏评分(P0.05)均有所降低,治疗组疗效优于对照组;治疗后两组NYHA心功能分级(P0.05)均得以改善,且治疗组改善更为明显(P0.05);在NTpro-BNP方面治疗后降低了两组NTpro-BNP水平(P0.01),且治疗组较对照组NTpro-BNP下降的更明显;两组患者治疗后左室射血分数(LVEF)均得以提高,且治疗组提高更为明显(P0.05)。所有患者服药依从性较高,在治疗过程中未因出现严重不良反应而中断治疗,血液生化检查均处于正常范围内。结论:通过本次临床观察可以看出心力健丸治疗心肺气虚、血瘀水停型慢性心力衰竭可明显降低中医症状积分与Lee氏心衰疗效积分,改善患者心衰的症状,降低全血NT-pro BNP水平,改善机体钠水储留,减轻心脏负荷,提高慢性心力衰竭患者心功能水平。治疗过程中无明显毒副作用。配合西药常规治疗,标本兼治,在临床上疗效取得良好的效果。
[Abstract]:Objective: this clinical observation is to use Xinlijian pills combined with western medicine to treat patients with chronic heart failure with deficiency of heart and lung qi, blood stasis and water stasis, and observe its therapeutic effect. To explore and analyze the mechanism of action in theory, to provide a new Chinese patent medicine for the treatment of chronic heart failure, so as to broaden the treatment method of chronic heart failure and facilitate its practical application. Methods: from December 2015 to December 2016, 60 patients with chronic heart failure (CHF) with central lung qi deficiency and blood stasis and water stagnation were selected from Department of Cardiology, Huangpi District traditional Chinese Medicine Hospital, Wuhan City. Their heart function was in II-III grade (NYHA grade). 60 patients were randomly divided into treatment group (n = 30) and control group (n = 30). Xinlijian Pill is a research and development preparation in our hospital. It is made into water pill by the decoction room of our hospital. The course of treatment is 3 months, and the method is taken 3 times a day, 15 capsules per time. Before and after treatment, TCM symptom score, NYHA cardiac function grade, Lee's heart failure curative effect score, LVEF,NT-pro BNP level and blood biochemical index were observed. Results: after 3 months of treatment, both groups achieved good therapeutic effect. The results of clinical symptom score showed that the TCM syndromes score and Lee's score (P0.05) of the two groups decreased after treatment. The curative effect of the treatment group was better than that of the control group. After treatment, the NYHA cardiac function grading (P0.05) was improved in both groups, and the improvement was more obvious in the treatment group (P0.05). After NTpro-BNP treatment, the level of NTpro-BNP was decreased in both groups (P0.01), and the decrease of NTpro-BNP in the treatment group was more obvious than that in the control group. Left ventricular ejection fraction (LVEF) was significantly increased in both groups (P0.05). All the patients had high compliance, no serious adverse reactions occurred during the treatment, and the blood biochemical examination was within the normal range. Conclusion: through this clinical observation, it can be seen that Xinlijian Pill can significantly reduce the scores of TCM symptoms and the curative effect of Lee's Heart failure in treating chronic heart failure with deficiency of heart and lung qi, blood stasis and water stagnation, and improve the symptoms of heart failure in patients. The level of NT-pro BNP in whole blood was decreased, the retention of sodium and water was improved, the cardiac load was alleviated, and the cardiac function was improved in patients with chronic heart failure. There were no obvious side effects during the treatment. In combination with routine treatment of western medicine, both symptoms and symptoms have been treated, and good results have been achieved in clinical treatment.
【学位授予单位】：湖北中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R259
[Abstract]:Objective: this clinical observation is to use Xinlijian pills combined with western medicine to treat patients with chronic heart failure with deficiency of heart and lung qi, blood stasis and water stasis, and observe its therapeutic effect. To explore and analyze the mechanism of action in theory, to provide a new Chinese patent medicine for the treatment of chronic heart failure, so as to broaden the treatment method of chronic heart failure and facilitate its practical application. Methods: from December 2015 to December 2016, 60 patients with chronic heart failure (CHF) with central lung qi deficiency and blood stasis and water stagnation were selected from Department of Cardiology, Huangpi District traditional Chinese Medicine Hospital, Wuhan City. Their heart function was in II-III grade (NYHA grade). 60 patients were randomly divided into treatment group (n = 30) and control group (n = 30). Xinlijian Pill is a research and development preparation in our hospital. It is made into water pill by the decoction room of our hospital. The course of treatment is 3 months, and the method is taken 3 times a day, 15 capsules per time. Before and after treatment, TCM symptom score, NYHA cardiac function grade, Lee's heart failure curative effect score, LVEF,NT-pro BNP level and blood biochemical index were observed. Results: after 3 months of treatment, both groups achieved good therapeutic effect. The results of clinical symptom score showed that the TCM syndromes score and Lee's score (P0.05) of the two groups decreased after treatment. The curative effect of the treatment group was better than that of the control group. After treatment, the NYHA cardiac function grading (P0.05) was improved in both groups, and the improvement was more obvious in the treatment group (P0.05). After NTpro-BNP treatment, the level of NTpro-BNP was decreased in both groups (P0.01), and the decrease of NTpro-BNP in the treatment group was more obvious than that in the control group. Left ventricular ejection fraction (LVEF) was significantly increased in both groups (P0.05). All the patients had high compliance, no serious adverse reactions occurred during the treatment, and the blood biochemical examination was within the normal range. Conclusion: through this clinical observation, it can be seen that Xinlijian Pill can significantly reduce the scores of TCM symptoms and the curative effect of Lee's Heart failure in treating chronic heart failure with deficiency of heart and lung qi, blood stasis and water stagnation, and improve the symptoms of heart failure in patients. The level of NT-pro BNP in whole blood was decreased, the retention of sodium and water was improved, the cardiac load was alleviated, and the cardiac function was improved in patients with chronic heart failure. There were no obvious side effects during the treatment. In combination with routine treatment of western medicine, both symptoms and symptoms have been treated, and good results have been achieved in clinical treatment.
【学位授予单位】：湖北中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R259
【参考文献】
相关期刊论文 前10条
1 闫秋林;毛以林;;毛以林辨证论治慢性心衰经验[J];世界中西医结合杂志;2016年04期
2 王U，
本文编号：2382721
本文链接：https://www.wllwen.com/zhongyixuelunwen/2382721.html
最近更新
教材专著
